Aparito

Aparito is a global health technology company that digitizes clinical trials to accelerate drug development, particularly for rare diseases. The company provides the Atom5™ platform, an integrated, patient-centric solution that enables remote patient monitoring through mobile apps, video assessments, and wearable devices, allowing patients to participate in clinical research from their homes. Following its acquisition in July 2024, Aparito operates as a wholly owned subsidiary of Eli Lilly and Company. The company continues to maintain its headquarters in Wrexham, Wales, and focuses on developing digital endpoints and real-world data to improve patient experience and trial outcomes globally.